New data show sustained five-year benefit of UCB's Neupro for RLS

New data presented at the 62nd American Academy of Neurology annual meeting being held in Toronto, Canada, showed that patients with moderate to severe Restless Legs Syndrome (RLS) using Belgian drugmaker UCB's Neupro (rotigotine) achieved sustained improvements in symptoms over five years of treatment.

"Many people with RLS will have spent months or years trying to get a diagnosis and find a treatment that can help them. So these five-year results provide additional evidence that, once they start using rotigotine, people with RLS may experience long term relief from their symptoms, and a significant proportion may become symptom free," said Diego Garcia-Borreguero, Director of the Sleep Research Institute in Madrid, Spain.

Longest placebo-controlled study in RLS